Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure

Autor:	Thomas E. Love, Richard M. Allman, Finn Waagstein, Wilbert S. Aronow, Charity J. Morgan, Prakash Deedwania, Kumar Sanam, Vikas Bhatia, Stefan D. Anker, Javed Butler, Navkaranbir S. Bajaj, Peter E. Carson, Ross D. Fletcher, Raya Kheirbek, Taimoor Hashim, Gregg C. Fonarow, Ali Ahmed, Sumanth D. Prabhu
Rok vydání:	2015
Předmět:	Male Inotrope medicine.medical_specialty Time Factors medicine.drug_class Adrenergic beta-Antagonists Kaplan-Meier Estimate Medicare Patient Readmission Risk Assessment Drug Administration Schedule Article Cause of Death Internal medicine Confidence Intervals medicine Humans Hospital Mortality Beta blocker Aged Proportional Hazards Models Cause of death Aged 80 and over Ejection fraction Dose-Response Relationship Drug Proportional hazards model business.industry Patient Protection and Affordable Care Act Hazard ratio General Medicine Middle Aged medicine.disease Survival Analysis Patient Discharge United States Confidence interval Treatment Outcome Heart failure Cardiology Female business Follow-Up Studies Heart Failure Systolic
Zdroj:	The American Journal of Medicine. 128:715-721
ISSN:	0002-9343
DOI:	10.1016/j.amjmed.2014.11.036
Popis:	BACKGROUND: Beta-blockers improve outcomes in patients with systolic heart failure. However, it is unknown whether their initial negative inotropic effect may increase 30-day all-cause readmission, a target outcome for Medicare cost reduction and financial penalty for hospitals under the Affordable Care Act. METHODS: Of the 3067 Medicare beneficiaries discharged alive from 106 Alabama hospitals (1998-2001) with a primary discharge diagnosis of heart failure and ejection fraction (EF)
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93c2c8095ffd6d3a2020a562ff820420 https://doi.org/10.1016/j.amjmed.2014.11.036 Zobrazit plný text záznamu